Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Document Type
Journal Article
Publication Date
12-1-2016
Journal
Lancet HIV
Volume
3
Issue
12
Inclusive Pages
e561-568
DOI
10.1016/S2352-3018(16)30121-7
Keywords
Adenine; Adolescent; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Thailand; Uganda; United States; Viral Load
APA Citation
Gaur, A., Kizito, H., Prasitsueubsai, W., Rakhmanina, N., Rassool, M., Chakraborty, R., Batra, J., Kosalaraksa, P., Luesomboon, W., Porter, D., Shao, Y., Myers, M., Ting, L., SenGupta, D., Quirk, E., & Rhee, M. (2016). Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.. Lancet HIV, 3 (12). http://dx.doi.org/10.1016/S2352-3018(16)30121-7
Peer Reviewed
1
